DB103

DB103 is a synthetic analogue of apigenin, identified as a novel multi-effective heterocyclic compound. It functions as an anti-restenotic agent and interferes with angiogenesis, a critical process in tumor progression. The compound demonstrates a superior ability compared to apigenin in modulating proangiogenic responses triggered by an inflammatory microenvironment. It is being explored for targeted and prolonged release through cyclodextrin-based nanosponges, particularly for local therapy aimed at vessel walls following percutaneous intervention.

Other names

2-(3,4-dimethoxyphenyl)-3-phenyl-4H-pyrido[1,2-a] pyrimidin-4-one